TY - JOUR
T1 - Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies
AU - Crivellari, Diana
AU - Galligioni, Enzo
AU - Frustaci, Sergio
AU - Gasparini, Giampietro
AU - Vaccher, Emanuela
AU - Re, Giovanni Lo
AU - Talamini, Renato
AU - Monfardini, Silvio
AU - Ambroso, Giovanni
PY - 1989
Y1 - 1989
N2 - In an attempt to define the activity and toxicity of low-dose aminoglutethimide plus steroid replacement in advanced breast cancer, we treated 40 patients with aminoglutethimide 500 mg/day + hydrocortisone 50 mg/day. Previous treatment consisted of additive hormones in 29 patients, oophorectomy in 8, and chemotherapy in 32. Among the 37 patients evaluablefor response and toxicity, 5 objective responses (16.2% and 20 stable diseases (54% were noted. Toxicity, absent in 23 patients (62.I % and mild in 14, consisted mainly of Grade I (WHO) nausea, drowsiness, cutaneous rash, and dizziness. Responders and patients with stable disease experienced a similar survival (median not reached at 22 months). Aminoglutethimide at low doses appears to be beneficial in patients refractory to conventional therapies even if the objective response rate is low.
AB - In an attempt to define the activity and toxicity of low-dose aminoglutethimide plus steroid replacement in advanced breast cancer, we treated 40 patients with aminoglutethimide 500 mg/day + hydrocortisone 50 mg/day. Previous treatment consisted of additive hormones in 29 patients, oophorectomy in 8, and chemotherapy in 32. Among the 37 patients evaluablefor response and toxicity, 5 objective responses (16.2% and 20 stable diseases (54% were noted. Toxicity, absent in 23 patients (62.I % and mild in 14, consisted mainly of Grade I (WHO) nausea, drowsiness, cutaneous rash, and dizziness. Responders and patients with stable disease experienced a similar survival (median not reached at 22 months). Aminoglutethimide at low doses appears to be beneficial in patients refractory to conventional therapies even if the objective response rate is low.
UR - http://www.scopus.com/inward/record.url?scp=0024416858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024416858&partnerID=8YFLogxK
U2 - 10.3109/07357908909038277
DO - 10.3109/07357908909038277
M3 - Article
C2 - 2790534
AN - SCOPUS:0024416858
VL - 7
SP - 113
EP - 116
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 2
ER -